Interview with Juergen Knackmuss, Chairman, GPHF
Could you briefly introduce our readers the how the GPHF managed to improve health care in developing countries since its foundation in 1987? The former abbreviation of GPHF stood for…
Address: Gesellschaft für Versuchsplanung und Datenanalyse mbH,Heimeranstr. 35,D-80339 Muenchen
Tel: +49-89-895286-0
Web: www.medicomp-cro.de
Established in 1985, Medicomp offers a wide range of services in drug and medical device development throughout Europe, from early conception of a study to the final report. The CRO conducts projects according to the most recent international standards and recommendations and according to own or Sponsor’s SOPs.
The company does not restrict the job to gain and analyse data and present results but adds medical and pharmaceutical expertise as well as personal commitment to the projects. Medicomp is member of the Federal Association of Contract Research Organisations, the BVMA, which implies regular system audits by independent auditors. The business is financially independent, receiving no funds from public or private institutions.
Could you briefly introduce our readers the how the GPHF managed to improve health care in developing countries since its foundation in 1987? The former abbreviation of GPHF stood for…
You have been leading GSK, one of the top five pharmaceutical companies in the German market, for just over a year, after having worked previously in Poland, the UK, France,…
Celgene is very new in the German market. What would you say have been the main achievements of Celgene Germany since its establishment in 2006? Celgene Germany started as a…
Could you briefly present the Association of German Biotechnology Companies (VBU) and DECHEMA e.V. to our readers and describe their importance to the German biotechnology industry? VBU is a non…
Hospira, which was spun-off from Abbott Laboratories in 2004, is a global specialty pharmaceutical and medication delivery company driven by its vision of Advancing Wellness™. Bringing proven leadership and experience,…
How challenging is for you as General Manager of Nycomed Germany to lead the number one subsidiary of the Nycomed Group and what would you highlight as the key milestones…
The acquisition of IVAX in 2006 was decisive to establish Teva as the number one generic producer worldwide and further consolidate the company in the German market; and this process…
Astellas has been present in the German market for almost two decades through Yamanouchi and Fujisawa. But since 2005 it gained a new identity thanks to the merger of the…
See our Cookie Privacy Policy Here
